T1	Participants 25 82	participants with depression and impaired quality of life
T2	Participants 472 536	participants with heart failure with preserved ejection fraction
T3	Participants 733 1080	patients enrolled in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT), 3400 patients completed the Kansas City Cardiomyopathy Questionnaire, 3395 patients completed European QOL 5D Visual Analog Scale, and 1431 patients in United States and Canada completed the Patient Health Questionnaire-9
